AI biotech company Owkin has teamed up with AstraZeneca to develop an AI-powered tool to prescreen for gBRCA mutations in breast cancer directly from digitized pathology slides. This tool aims to speed up and increase access to gBRCA testing, which is crucial in determining an individual’s risk for certain cancers. The collaboration underscores a commitment to advancing precision medicine and addressing unmet needs in cancer care. This partnership is part of a larger trend in the industry, with other companies like Mika Health and Absci also collaborating with AstraZeneca on projects focused on improving cancer treatments using digital therapeutics and AI technology.
Source link
Owkin, AstraZeneca partner to develop an AI gBRCA prescreen remedy for breast cancer
